Next Article in Journal
Dose-Response Modelling of Paralytic Shellfish Poisoning (PSP) in Humans
Next Article in Special Issue
Antipruritic Effects of Botulinum Neurotoxins
Previous Article in Journal
Characterization of Human Type C Enterotoxin Produced by Clinical S. epidermidis Isolates
Previous Article in Special Issue
A Study and Review of Effects of Botulinum Toxins on Mast Cell Dependent and Independent Pruritus
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessArticle
Toxins 2018, 10(4), 140; https://doi.org/10.3390/toxins10040140

“Appropriate Treatment” and Therapeutic Window in Spasticity Treatment with IncobotulinumtoxinA: From 100 to 1000 Units

Department of Basic Sciences, Neuroscience and Sense Organs, University of Bari “Aldo Moro”, G. Cesare Place 11, 70125 Bari, Italy
*
Author to whom correspondence should be addressed.
Received: 12 February 2018 / Revised: 21 March 2018 / Accepted: 23 March 2018 / Published: 28 March 2018
Full-Text   |   PDF [4872 KB, uploaded 3 May 2018]   |  

Abstract

Many neurological diseases (ischemic and hemorrhagic stroke, multiple sclerosis, infant cerebral palsy, spinal cord injuries, traumatic brain injury, and other cerebrovascular disorders) may cause muscle spasticity. Different therapeutic strategies have been proposed for the treatment of spasticity. One of the major treatments for tone modulation is botulinum toxin type A (BTX-A), performed in addition to other rehabilitation strategies based on individualized multidisciplinary programs aimed at achieving certain goals for each patient. Therapeutic plans must be precisely defined as they must balance the reduction of spastic hypertonia and retention of residual motor function. To perform and optimize the treatment, an accurate clinical and instrumental evaluation of spasticity is needed to determine how this symptom is invalidating and to choose the best doses, muscles and times of injection in each patient. We introduce an “appropriate treatment” and no “standard or high dosage treatment” concept based on our retrospective observational study on 120 patients lasting two years, according to the larger Therapeutic Index and Therapeutic Window of Incobotulinumtoxin A doses from 100 to 1000 units. We studied the efficiency and safety of this drug considering the clinical spasticity significance for specialist physicians and patients. View Full-Text
Keywords: spasticity; botulinum toxin type A; appropriate treatment; Therapeutic Index spasticity; botulinum toxin type A; appropriate treatment; Therapeutic Index
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Ianieri, G.; Marvulli, R.; Gallo, G.A.; Fiore, P.; Megna, M. “Appropriate Treatment” and Therapeutic Window in Spasticity Treatment with IncobotulinumtoxinA: From 100 to 1000 Units. Toxins 2018, 10, 140.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top